Interview: Alnylam President On Patisiran Lift-Off Plans
Barry Greene, president of Alnylam, tells Scrip that the company is happy to consider risk-sharing with payers, as the firm is confident about the 'extreme value' that its RNAi therapeutic for hATTR amyloidosis will offer, if approved.
You may also be interested in...
Scrip sat down with the CEOs of three emerging oncology companies in Israel that are all focused on targeted cancer treatments, to find out about upcoming milestones and novel technologies that are budding in the country.
Although Dicerna needs to make some payments to Alnylam to settle a patent infringement case, the company has avoided an expensive court trial and is free to find partners for its early-stage RNAi therapeutics programs.
Duo to equally share development costs and profits from any candidates emerging from their RNAi discovery pact.